CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
New Haven, Connecticut, United States and 73 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Harrison, New York, United States and 186 other locations
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...
Phase 1, Phase 2
Hawthorne, New York, United States and 31 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
New Haven, Connecticut, United States and 55 other locations
JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leu...
Phase 1
Stony Brook, New York, United States and 27 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
New Haven, Connecticut, United States and 74 other locations
Patients with non-Hodgkin Lymphoma will be treated with CD38-SADA:177Lu-DOTA complex (The IMP is a two-step radioimmunothe...
Phase 1
Stony Brook, New York, United States and 5 other locations
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study desi...
Phase 1
New Haven, Connecticut, United States and 3 other locations
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non...
Phase 2
New Haven, Connecticut, United States and 7 other locations
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...
Phase 2
Stony Brook, New York, United States and 137 other locations
Clinical trials
Research sites
Resources
Legal